VIDEO: ‘Eye-opening’ results suggest low-dose prednisone associated with adverse events
Click Here to Manage Email Alerts
SAN DIEGO — Jeffrey A. Sparks, MD, MMSc, spoke with Healio about two “high-impact” presentations from ACR Convergence 2023 that assessed dosing of prednisone for patients with rheumatoid arthritis.
Both abstracts evaluated the association of cardiovascular events among cohorts of patients with rheumatoid arthritis who were treated with glucocorticoids.
While the first abstract investigated the risk among veterans in the United States, the second was a population-based study in Hong Kong, according to Sparks, an associate professor of medicine at Harvard Medical School and an associate program director of the Rheumatology Fellowship, director of Immuno-Oncology and Autoimmunity and director of the Joint Biology Consortium Human Biosamples Core at Brigham and Women’s Hospital.
“This is a bit of a practice-affirming and kind of eye-opening study that even pretty low doses of prednisone seem to have adverse events relating to MACE,” he said.
Collapse
SO H, et al. Abstract 2170. Presented at: ACR Convergence 2023; Nov. 10-15, 2023; San Diego.
Wallace BI, et al. Abstract 2430. Presented at: ACR Convergence 2023; Nov. 10-15, 2023; San Diego.
Read more about
Click Here to Manage Email Alerts